COVID-19 symptom rebound. Cough, sore throat,diarrhea, stomach upset, clammy skin (when I woke up this morning)/oropharyngeal pain/diarrhoea/abdominal discomfort/cough/cold sweat; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19 symptom rebound. Cough, sore throat,diarrhea, stomach upset, clammy skin (when I woke up this morning)/oropharyngeal pain/diarrhoea/abdominal discomfort/cough/cold sweat) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 053E21A, 021B21A and 030A21A) for COVID-19 vaccination.     Concurrent medical conditions included GERD, ADHD, Blood pressure high and Drug allergy (allergy to unknown past drug). Concomitant products included AZELASTINE HCL, ESOMEPRAZOLE MAGNESIUM, CETIRIZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, FLUTICASONE PROPIONATE (FLUTICASONE PROPIONATE (GLUCOCORTICOID)) and TAMSULOSIN HYDROCHLORIDE for an unknown indication.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19 symptom rebound. Cough, sore throat,diarrhea, stomach upset, clammy skin (when I woke up this morning)/oropharyngeal pain/diarrhoea/abdominal discomfort/cough/cold sweat). At the time of the report, COVID-19 (COVID-19 symptom rebound. Cough, sore throat,diarrhea, stomach upset, clammy skin (when I woke up this morning)/oropharyngeal pain/diarrhoea/abdominal discomfort/cough/cold sweat) was resolving.            Unspecified Pfizer medication reported as cosuspect having start date 10-MAY-2022 and end date 15-May-2022 with indication COVID-19 treatment was reported.  Company comment: This is a spontaneous case concerning a 39-year-old, male patient with no relevant medical history and with vaccine history of receiving first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 28 days, who experienced the unexpected non-serious AESI event of Covid-19. The event occurred approximately 6 to 7 months after the third dose of mRNA-1273 vaccine administration. Allegedly the event was described as, patient experienced Covid-19 and treated with unspecified medication made by Pfizer with approximate duration of 5 days. Approximately 7 days after the treatment with unspecified medication made by Pfizer, patient's Covid-19 symptoms of cough, sore throat, diarrhea, stomach upset and clammy skin reoccurred. No other information surrounding the event was reported. The outcome of the event was reported as resolving. The current Covid-19 pandemic remain confounder for the event. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 39-year-old, male patient with no relevant medical history and with vaccine history of receiving first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 28 days, who experienced the unexpected non-serious AESI event of Covid-19. The event occurred approximately 6 to 7 months after the third dose of mRNA-1273 vaccine administration. Allegedly the event was described as, patient experienced Covid-19 and treated with unspecified medication made by Pfizer with approximate duration of 5 days. Approximately 7 days after the treatment with unspecified medication made by Pfizer, patient's Covid-19 symptoms of cough, sore throat, diarrhea, stomach upset and clammy skin reoccurred. No other information surrounding the event was reported. The outcome of the event was reported as resolving. The current Covid-19 pandemic remain confounder for the event. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.